Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02989467 · ClinicalTrials.gov registry record · Phase 1

Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying

A Phase 1 study, sponsored by Mayo Clinic.

Completed
Registry status
Phase 1
Development phase
27
Enrollment target

NCT02989467: Completed Phase 1 study, sponsored by Mayo Clinic.

NCT02989467 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 27 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02989467, a Phase 1 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 1
Development phase
27 participants
Enrollment target

Study Summary

This research study is being done to compare the effects of Aprepitant and placebo on fasting gastric volume, accommodation volume, satiation (fullness) and gastric emptying.

Primary Outcome

The time for half of the ingested solids to leave the stomach.

Interventions

  • DRUG Placebo
  • DRUG Aprepitant

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2017-01-27
Est. Completion 2018-01-01
Phase Phase 1
Mayo Clinic

2,844 total trials

What the finished NCT02989467 record still lists

NCT02989467 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02989467 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02989467 about?

NCT02989467 is a clinical study titled "Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying". This research study is being done to compare the effects of Aprepitant and placebo on fasting gastric volume, accommodation volume, satiation (fullness) and gastric emptying.

What is the current status of trial NCT02989467?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2017-01-27. Estimated completion is 2018-01-01.

What interventions are being tested in trial NCT02989467?

The interventions under investigation include: Placebo (DRUG), Aprepitant (DRUG).

Who is sponsoring clinical trial NCT02989467?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02989467's enrollment target sits among peer trials

27 1463rd of 2000 higher than 519 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00912041 · 27 participants · NA

    BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

  • NCT02847559 · 27 participants · Phase 2

    Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

  • NCT03380195 · 27 participants · NA

    Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness

  • NCT03384238 · 27 participants · Phase 1

    Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02989467, the US trial registry maintained by the National Library of Medicine. NCT02989467 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.